VEROVACCiNES secures a 7-digit financing to expand its vaccine pipeline
Vaccine specialist secures financing of 1.6 million euros
The veterinary vaccine developer VEROVACCiNES announces the successful comple tion of a €1.6 million financing round. The round was largely supported by existing investors as well as the founders. This underlines the joint confidence in the innovative strength and strategic direction of the company.
Following the rapid development of a highly efficacious vaccine against bluetongue virus type 3, VEROVACCiNES plans to use the funds raised specifically for the further expansion of its own product pipeline. The company will use its proprietary vaccine technology (Unified Vaccine Platform), which provides ONE coherent system for the generation, development, and production of innovative subunit vaccines along the entire value chain.
“The massive progress we have made over the past year in expanding our technology platform enables us to push ahead with the development of vaccines for our own pipeline and to launch further collaborations,” says Dr. Hanjo Hennemann, CEO of VEROVACCiNES. ”We are grateful to our investors for their support, which allows us to realize our ambitious development goals.”
The CSO of VEROVACCiNES, Prof. Sven-Erik Behrens, emphasizes the importance of the financing round: “With these funds, we can significantly accelerate our vaccine development and bring promising vaccine candidates to the next stage. Our goal is to bring innovative and efficacious vaccines to the market to meet the increasing challenges in animal health long term.”
The investor consortium, consisting of renowned investors from various European countries, is counting on VEROVACCiNES' potential to further revolutionize biotechnological vaccine development and to efficiently develop innovative products with high unique selling points.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.